Axitinib
Clear Cell Renal Carcinoma
University of California, San FranciscoSmall moleculePhase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
24 Active assets in the Clear Cell Renal Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Peking University First Hospital | Phase 2 | BB |
Nivolumab Exelixis | Phase 2 | B |
Pazopanib Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Phase 2 | B |
Belzutifan José Claudio Casali da Rocha | Phase 2 | B |
Zanzalintinib Kelly Fitzgerald, MD | Phase 2 | B |
View all 39 →
Same molecule, other indications
Axitinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →